"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 4 | 6 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 8 | 8 |
| 2003 | 3 | 2 | 5 |
| 2004 | 7 | 3 | 10 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 3 | 7 |
| 2009 | 7 | 2 | 9 |
| 2010 | 13 | 5 | 18 |
| 2011 | 11 | 5 | 16 |
| 2012 | 9 | 3 | 12 |
| 2013 | 8 | 5 | 13 |
| 2014 | 8 | 3 | 11 |
| 2015 | 10 | 4 | 14 |
| 2016 | 9 | 8 | 17 |
| 2017 | 11 | 11 | 22 |
| 2018 | 6 | 9 | 15 |
| 2019 | 10 | 10 | 20 |
| 2020 | 10 | 9 | 19 |
| 2021 | 7 | 14 | 21 |
| 2022 | 1 | 18 | 19 |
| 2023 | 1 | 9 | 10 |
| 2024 | 14 | 11 | 25 |
| 2025 | 15 | 2 | 17 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention. Diabetes Care. 2026 Feb 01; 49(2):344-351.
-
Baseline characteristics in the SYNCHRONIZE?-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb; 28(2):1490-1498.
-
Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation. Clin Transplant. 2025 Oct; 39(10):e70344.
-
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025 Aug 01; 48(8):1386-1394.
-
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes. Curr Atheroscler Rep. 2025 Jul 30; 27(1):76.
-
Low-dose metformin requires brain Rap1 for its antidiabetic action. Sci Adv. 2025 Aug; 11(31):eadu3700.
-
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies. Cardiovasc Drugs Ther. 2026 Apr; 40(2):779-793.
-
The interplay between asthma and type 2 diabetes mellitus: mutual interactions and therapeutic implications. Expert Rev Clin Immunol. 2025 Jun; 21(6):683-699.
-
Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug na?ve type 2 diabetes patients. J Diabetes Complications. 2025 Sep; 39(9):109080.
-
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges. Pharmacol Res. 2025 Jun; 216:107770.